Currently, we are conducting a randomized, phase II clinical trial to test the hypothesis that a 16-week digital risk factor modification program will improve 10-year ASCVD risk score as compared to usual care in men with potentially lethal prostate cancer receiving at least LHRH agonist or antagonist (ProTrio; NCT05054296). The gene discussed is GNRH1; the disease is Familial prostate cancer.